LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Avatud

SektorTervishoid

16.24 3.37

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

15.37

Max

16.24

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+4.71% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.33%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	60M 311M
Eelmine avamishind	12.87
Eelmine sulgemishind	16.24

Uudiste sentiment

By Acuity

19%

81%

25 / 344 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. mai 2026, 21:33 UTC

Tulu

Correction to Salesforce 1Q Sales, Profit Rise Article

27. mai 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. mai 2026, 20:18 UTC

Tulu

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. mai 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. mai 2026, 21:08 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. mai 2026, 21:02 UTC

Tulu

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. mai 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. mai 2026, 20:55 UTC

Tulu

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. mai 2026, 20:48 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. mai 2026, 20:45 UTC

Tulu

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. mai 2026, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Webster Financial Stockholders Approve Sale to Banco Santander

27. mai 2026, 20:32 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. mai 2026, 20:30 UTC

Tulu

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. mai 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. mai 2026, 20:22 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:16 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. mai 2026, 20:13 UTC

Tulu

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

4.71% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 4.71%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

25 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.